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Coronary heart disease (CHD) caused by the narrowing of arteries
that feed the heart is the UK's single biggest killer, being responsible
for ~73,000 deaths each year, an average of 200 people each day.
Acute myocardial infarctionl (MI) represents the most harmful form of
CHD. Over the last decade, mortality due to CHD has declined in the
UK, but more people live with secondary consequences. In fact, most
of the current treatments are palliative, i.e. they reduce symptoms asso-
ciated with heart dysfunction, without providing a deﬁnitive repair.
Consequently, CHD patients undergo a progressive decline in the
pumping function of the heart that ultimately leads to heart failure
(HF). Today, post-infarct HF is the leading cause of invalidity, hospitali-
zation and mortality in patients over 65. In 2012–13, the UK National
Health System (NHS) expenditure for cardiovascular disease was
£7.02billion, 63% of which devoted to secondary care (Bhatnagar,
Wickramasinghe, Williams, Rayner, & Townsend, 2015) The NHS ana-
lysts have predicted a mismatch between total budget and patient
needs of nearly £30 billion by 2020/21. Therefore, efﬁciency actions to
increase quality and reduce expenditure growth are essential for all ser-
vices, including those for treatment and care of CHD patients. However,
efﬁciency alone may not sufﬁce without the introduction of new tech-
nologies having a transformative impact on this unmet clinical ﬁeld.
1.1. The urgent need for new therapies
Current care of CHD comprises pharmacotherapy and
revascularisation. However, medical treatment can be ineffective as in
the case of refractory angina (which has an estimated prevalence of
1.8 million in the USA and an incidence of 30–50,000/year in Europe).
Additionally, a steadily increasing number of patients fall into the
category in which revascularization cannot be applied or fails because
of restenosis. This is especially true of patients with occlusive pathology
extending to the microcirculation and diabetic or elderly patients who
have had multiple bypasses and stenting operations. Also, the most
important limitation of current treatments is that they do not replace
cells irreversibly damaged by ischaemia.
Cardiovascular regenerative medicine is a fast-growing ﬁeld of re-
search that aims to improve the treatment of CHD through innovative
restorative methods, such as gene therapy, stem cell therapy and tissue
engineering (Assmus et al., 2002; Wollert et al., 2004). Clinical studies
with skeletal myoblasts, bone marrow-derived cells, mesenchymal
stem cells (MSCs) and cardiac stem cells (CSCs) have shown feasibility
and initial evidence of efﬁcacy (Assmus et al., 2002; de Jong,
Houtgraaf, Samiei, Boersma, & Duckers, 2014; Hare et al., 2009;
Menasche et al., 2008; Sant'anna et al., 2010). After multiple systematic
reviews and meta-analyses, the consensus is that transplantation of
adult bonemarrow cellsmodestly improves ventricular function, infarct
size, and remodeling in patients with CHD compared with standard
therapy, and these beneﬁts persist during long-term follow-up
(Martin-Rendon, 2016). Bone marrow cell transplantation also reduces
the incidence of death, recurrent MI, and stent thrombosis in patients
with CHD (Jeevanantham et al., 2012). Moreover, Steven Chamuleau,
Andreas Zieher and collegaues have recently utilized interactionmodels
in a multivariable fashion to identify subgroups of patients that are de-
ﬁned as potential treatment responders, while simultaneously
correcting for relevant factors that affect general disease outcome. This
kind of approach could be the next step towards optimal cell therapy
in clinical care (Zwetsloot et al., 2016).
The SCIPIO clinical trial, the ﬁrst in man to investigate c-kit+ CSCs,
reported that 16 patients with ischemic cardiomyopathy received
intracoronary infusions of 0.5-1 × 106 c-kit+, autologous CSCs and
compared to controls these patients beneﬁted from an 8 and 12 unit
increase in left ventricular ejection fraction, 4 and 12months after infu-
sion, respectively (Bolli et al., 2011). A subset of 7 patients was subject
to cMRI analysis, which showed that the infarct region had signiﬁcantlydecreased in size by ~10 g up to 12months following c-kit+ CSC trans-
plantation (Bolli et al., 2011).
However, there is a persisting dispute regarding the mechanisms
underpinning the beneﬁt of cell therapy. The direct contribution of
transplanted cells in vascular and cardiac reconstitution has been
questioned (Balsam et al., 2004; Murry et al., 2004), and presently the
concept of paracrine promotion of spontaneous healing processes
prevails (Gnecchi et al., 2005; Tang et al., 2016a,b). Indeed, the general
consensus is that cell therapy and resultant improvements in cardiac
function and decreased infarct size in human trials is due to a ‘paracrine’
effect (Tang et al., 2016a,b). However, the lack of cardiomyocyte differ-
entiation capability of bonemarrow cells or CSCs could be due to lack of
characterisation of the transplanted cell type, poor cell survival and re-
tention, hostile host environment and subsequent restriction of cell pro-
liferation, integration and differentiation in this damage-regeneration
infarct model.
Despite the adult mammalian heart being composed of terminally
differentiated cardiomyocytes that are permanently withdrawn from
the cell cycle (Chien & Olson, 2002; Nadal-Ginard, 1978), it is now ap-
parent that the adult heart has the capacity, albeit low, to self-renew
cardiomyocytes over the human lifespan (Bergmann et al., 2012,
2015). This is supported by the detection of small, newly-formed,
immature cardiomyocytes, which incorporate BrdU/EdU and/or stain
positive for Ki67, Aurora B, and embryonic/neonatal myosin heavy
chain, aswell as cardiomyocytes undergoingmitosis, under normal con-
ditions and in response to diverse pathological and physiological stimuli
(Bergmann et al., 2015; Bostrom et al., 2010; Ellison et al., 2013;
Urbanek et al., 2003, 2005; Waring et al., 2014). The source of these
newly formed cardiomyocytes is a matter of debate (Laﬂamme &
Murry, 2011). Three main sources of origin of the new cardiomyocytes
have been claimed: (a) circulating progenitors, which through
the bloodstream home to the myocardium and differentiate into
cardiomyocytes (Quaini et al., 2002); (b) mitotic division of the pre-
existing cardiomyocytes (Bersell, Arab, Haring, & Kuhn, 2009; Bostrom
et al., 2010; Engel, Hsieh, Lee, & Keating, 2006; Senyo et al., 2013);
and (c) a small population of residentmultipotent stem cells able to dif-
ferentiate into the main cell types of the heart (i.e., cardiomyocytes,
smooth and endothelial vascular and connective tissue cells)
(Rasmussen et al., 2014; Torella, Ellison, Karakikes, & Nadal-Ginard,
2007).
Blood-borne precursors, althoughwell documented for having a role
in inﬂammation and healing, and when adult mouse bonemarrow cells
were injected into the chick embryo they converted to a myocardial
phenotype (Eisenberg, Burch, & Eisenberg, 2006), their cardiomyogenic
potential in the damaged adult heart is very limited, if any (Ellison et al.,
2013; Loffredo, Steinhauser, Gannon, & Lee, 2011). The evidence so far
presented in support of re-entry of terminally differentiated
cardiomyocytes into the cell cycle has been limited to show division of
cells that express proteins of the contractile apparatus in their cyto-
plasm (Bersell et al., 2009; Bostrom et al., 2010; Kuhn et al., 2007;
Senyo et al., 2013). This evidence is equally compatible with new
myocyte formation from the pool of multipotent cardiac stem/progeni-
tor cells, which as precursor cells express contractile proteins and be-
cause newly born myocytes are not yet terminally differentiated they
are capable of a few rounds of division before irreversibly withdrawing
from the cell cycle (Nadal-Ginard, 1978; Nadal-Ginard, Kajstura,
Anversa, & Leri, 2003). However, the mechanisms underlying a strict
postmitotic state in the heart during pathological remodeling have yet
to be fully elucidated (Zebrowski, Becker, & Engel, 2016).
The best documented source of the small, immature, newly formed
cardiomyocytes in the adult mammalian heart, including the human
(Torella, Ellison, Mendez-Ferrer, Ibanez, & Nadal-Ginard, 2006), is a
small population of endogenous cardiac stem and progenitor cells
(eCSCs) distributed throughout the atria and ventricles, which are
clonogenic, self-renewing and can give rise to functional cardiomyocytes
and vasculature in vitro and in vivo. Importantly, owing to genetic
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formed cardiomyocytes observed in the adult mammalian heart are
the product of eCSC differentiation (Ellison et al., 2013; Hsieh et al.,
2007; van Berlo & Molkentin, 2014).
Here, we provide an overview of current knowledge regarding
the therapeutic potential of using the stem cell-derived secretome in-
stead of source stem cell therapy to repair and regenerate the damaged
heart. Furthermore, we illustrate methodological aspects of secretome-
based cardiovascular regenerative medicine, with particular reference
to functional transcriptomics and proteomics as a combinatory strategy
to cherry pick the most beneﬁcial components of the stem cell
secretome. Finally, we report current evidence regarding the salutary
aspects of the secretome from two stem cell populations, namely CSCs
and pericytes.
2. Generation of a therapeutic product from stem cell secretome
Stem cells secrete potent combinations of cytokines, growth factors,
enzymes,microvesicles/exosomes and geneticmaterial, whichhelp car-
diac repair and regeneration at multiple points. The stem cell secretome
supports cardiomyocyte survival and proliferation, differentiation of
resident stem cells, and neovascularization, while limiting inﬂammato-
ry and pro-ﬁbrotic processes (Baraniak &McDevitt, 2010; Gnecchi et al.,
2005; Rao et al., 2015; Zhou et al., 2011). Some paracrine factors have
pleiotropic actions. For instance, one of the key pathways in stem cell-
based cardiac repair is the stromal cell-derived factor-1 (SDF-1)/
CXCR4 axis. It was proposed that substituting SDF-1 gene therapy for
source stem cells might represent a sensible therapeutic approach
(Penn, 2009). The blinded placebo-controlled STOP-HF trial demon-
strated a single endocardial administration of plasmid SDF-1 is safe, at-
tenuates left ventricle remodeling and improves ejection fraction in
ischaemic cardiomyopathy (Chung et al., 2015). However, there are
also paracrine factors that boost speciﬁc responses, thereby providing
a more deﬁned approach for selective treatments inspired by the stem
cell secretome. For instance, mesenchymal stem cell-derived Insulin
Growth Factor-1 (IGF-1) and ABI Family Member 3 Binding Protein
(Abi3bp) reportedly induce resident CSC mobilization (Mourkioti &
Rosenthal, 2005) and differentiation to the cardiac lineage, (Engels
et al., 2014; Hodgkinson et al., 2014) while CSC-derived basic Fibroblast
Growth Factor (bFGF), Vascular Growth Factor-A (VEGF-A) andHepato-
cyte Growth Factor (HGF) exert potent pro-angiogenic effects (Rao
et al., 2015; Zhou et al., 2011).
Intracoronary administration of IGF-1 and HGF, in doses ranging
from 0.5 to 2 μg HGF and 2 to 8 μg IGF-1, just below the site of left ante-
rior descendent occlusion, 30 min after MI during coronary reperfusion
in the pig, triggered a regenerative response from the CSCs, which is po-
tent and able to produce physiologically signiﬁcant regeneration of the
damaged myocardium (Ellison et al., 2011). IGF-1 and HGF induced
CSC migration, proliferation and functional cardiomyogenic and
microvasculature differentiation. Furthermore, IGF-1/HGF, in a dose-
dependent manner, improved cardiomyocyte survival, and reduced
ﬁbrosis and cardiomyocyte reactive hypertrophy. Interestingly, the
effects of a single administration of IGF-1/HGF is still measurable
2 months after its application, suggesting the existence of a feedback
loop triggered by the external stimuli that activate the production of
growth and survival factors by the targeted cells, which explains the
persistence and long duration of the regenerative myocardial response.
These histological changes were correlated with a reduced infarct size
and an improved ventricular segmental contractility and ejection frac-
tion at the end of the follow-up assessed by cMRI (Ellison et al., 2011).
Neuregulin-1 (NRG-1) is another key factor implicated in stimu-
lating cardiac repair and regeneration (Wadugu & Kuhn, 2012;
Waring et al., 2014). An Ig-domain containing form of NRG-1β,
also known as glial growth factor 2 (GG2) has been shown to im-
prove left ventricular ejection fraction and remodeling in pigs
post-MI, compared to controls (Galindo et al., 2014). It is thoughtthat NRG-1 imparts functional beneﬁts by activating and increasing
eCSC proliferation (Waring et al., 2014), inducing cardiomyocyte re-
placement (Bersell et al., 2009; Cohen et al., 2014; Polizzotti et al.,
2015). A bioengineered hydrogel system enables targeted and
sustained intramyocardial delivery of NRG-1, activating the cardio-
myocyte cell cycle and enhancing ventricular function in a murine
model of ischemic cardiomyopathy (Cohen et al., 2014), protecting
cardiomyocytes from apoptosis and improving mitochondrial func-
tion (Galindo et al., 2014). However, the role of NRG-1 in inducing
cardiomyocyte proliferation in the adult heart has been challenged,
with NRG1β1 treatment not increasing cardiomyocyte DNA synthe-
sis and consequent cardiomyocyte renewal in normal or infarcted
adult mouse hearts (Reuter, Soonpaa, Firulli, Chang, & Field, 2014).
Therefore, the role of NRG-1 administration in inducing cardiomyo-
cyte proliferation and replacement in the adult failing heart remains
controversial.
The stem cell secretome is collected in a form of cell culture condi-
tioned medium (CM) or supernatant. The use of stem cell-derived
secretome has several advantages compared to the use of stem cells,
as CM can be manufactured, sterilized, freeze-dried, packaged, stored
and transportedmore easily. Therefore, the stemcell-derived secretome
has a promising prospect to become a successful pharmaceutical/me-
dicinal product for regenerativemedicine. On the other hand, variability
represents a major limitation. The ﬁrst level of inconsistency is repre-
sented by inter-individual variability, due to the patient's characteris-
tics. Culture conditions, growth media and passages also affect the
composition of CM, as recently reviewed (Pawitan, 2014). In someocca-
sions, changes in culture conditions are intentionally introduced to en-
hance the production of certain biological components. For instance,
stem cells could be exposed to hypoxic conditions, with the aim of stim-
ulating the production of growth factors (Di Santo et al., 2009;
Ranganath, Levy, Inamdar, & Karp, 2012). The three-dimensional spher-
oid culture of human adipose-derived stem cells with clinically relevant
medium composed of amino acids, vitamins, glucose, and human serum
leads to 23- to 27-fold higher production of angiogenic factors than that
by conventional monolayer culture (Bhang et al., 2014). On the other
hand, the purity of preparations may become an issue when complete
growth medium is used, or collection of CM is performed shortly after
removal of growth medium supplements. In this case, contamination
may derive from the presence of left-over serum carrier proteins, due
to dynamic recycling of extracellular proteins by cellular vesicles (Iso
et al., 2014). The presence of serum or culture media in the CM- or
supernatant-derived product might elicit immune responses and/or
side effects. In this respect, alternative methods to culture cells (such
as the adoption of serum-free culture, etc) and the reﬁnement of the
CM-derived secretome products should be considered. However, a re-
cent study indicates that the formation of complexes of serum-derived
immunoglobulins with paracrine factors could enhance the stability
and biological activity of the CM therapeutic component (Rao et al.,
2015). A challenging objective of future research is to deﬁne the
whole composition of crude CM preparations, measure activity of the
main components and determine therapeutic doses. In this respect,
manufacturing and quality control protocols need to be further reﬁned
and standardized to accomplish the classical regulatory path for drugs.
The goal is to generate synthetic versions, inspired by the stem cell
secretome, containing consistent dosages of therapeutic factors for the
treatment of thousand patients.
2.1. Methodologies to determine the therapeutic component
Different methods have been used for studying the secretome
composition and for distinguishing the essential components that
are advantageous for therapeutic applications. Multiplex antibody-
based techniques, such as antibody arrays, have high sensitivity
(in the range of 1–10 pg/ml), speciﬁcity, and reproducibility across
a broad range of concentrations. High-throughput analysis of the
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has identiﬁed about 40 proteins with high expression levels
(Parekkadan et al., 2007). Studies using multiplex antibody-based
arrays showed the contribution of MSC-derived paracrine factors
in determining cardiac improvement in a swine MI models
(Nguyen et al., 2010) and the participation of angiogenin, a secreted
ribonuclease that inhibits protein translation under stress condi-
tions, in promotion of cardiomyocyte survival by intramyocardially
injected bone marrow-derived mononuclear cells (Ascione et al.,
2015). However, a common drawback of antibody-based techniques
(e.g., ELISA and antibody arrays) consists of the limited availability of
antibodies to detect secreted proteins.
Liquid Chromatography with TandemMass Spectrometry Detection
(LC-MS/MS) has beenwidely used for characterizing the secretomepro-
ﬁle. For example, a study using this technique demonstrated that pre-
conditioning of human adipose-derived MSCs with Tumor Necrosis
Factor-alpha (TNF-α) leads to enhanced expression of cytokines and
chemokines such as Interleukin-6 (IL-6), Interleukin-8 (IL-8),Monocyte
chemoattractant protein-1 (MCP-1), metalloproteinases (MMPs),
Pentraxin-related protein, and Cathepsin L. in CM (Lee et al., 2010).
On the other hand, gel-based and LC-MS/MS techniques have limited
sensitivity to detect molecules that are present in fmol concentrations
(Ranganath et al., 2012).
RNA interference, by siRNA or shRNA, represents a powerful method
to evaluate the function of candidate genes (Lemons, Maurya,
Subramaniam, & Mercola, 2013). Throughput interference screening of
mRNAs and microRNAs in cell-based assays can also help to decipher
the functional importance of single components of the stem cells
secretome. It is necessary to validate the outcome of silencing by rescue
experiments where the CM from silenced cells is supplemented with a
candidate recombinant protein to determine if it restores the original
phenotype. Fig. 1 illustrates an application of siRNA technology to the
discovery of CM components implicated in the activation of stem cell
migration.
A more systematic approach to tackling the secretome complexity
combines LC-MS/MS detection, antibody arrays,microarrays, and bioin-
formatics. This approach identiﬁed 201 unique proteins (132 using LC-
MS/MS and 72 using antibody arrays) typical of humanMSC secretome
(Sze et al., 2007). Also, Sze exploited a computational analysis of data to
predict the roles of the secretome components in metabolism, immune
response, and development.Fig. 1. Cardiac stem cellmigration-based siRNA secretome screening. (1) Source cells are transfe
genes. (2) After removal of transfecting agents, source cells are cultured for 48 h and then the CM
migration. (3) Migrated stem cells (stainedwith nuclear Hoechst) are enumerated using a high
as TandemMass Spectrometry, to perform system analysis of the secretome.2.2. Pre-clinical cardiovascular studies using stem cell-derived secretome
Some preclinical studies have demonstrated that delivery of stem cell-
derived CM has salutary effects in models of limb and myocardial ischae-
mia. Table 1 summarizes some fundamental investigations that evaluated
the effect of crude CMpreparations. A study using an intra-muscular injec-
tion of endothelial progenitor cell-derived CM (EPC-CM) collected under
hypoxia showed outcomes (i.e. tissue revascularization and functional re-
covery) similar to cell transplantation in a model of limb ischaemia (Di
Santo et al., 2009). Similar beneﬁts have been reported with the use of
CM from human amniotic ﬂuid stem cells (Mirabella, Cilli, Carlone,
Cancedda, & Gentili, 2012), cord blood-derived EPCs (Kim et al., 2010)
and fetal aorta CD133 vascular cells (Barcelos et al., 2009) in limb ischae-
mia and wound healing models and with CM from EPCs (Hynes et al.,
2013) and MSCs in MI (See et al., 2011; Timmers et al., 2007, 2011; Yang
et al., 2013). Furthermore, the CM of human embryonic stem cell-
derived ECs reportedly restored the healing activity of circulating
proangiogenic cells from diabetic patients upon combined injection in
ischaemic limbs of severe combined immunodeﬁcient mice (Ho et al.,
2012). One important limitation of using CM for therapeutic uses consists
of the rapid degradation of therapeutic components in vivo. To obviate this
drawback, some investigators have used repeated injections of the CM in
preclinical studies, but this approach may be unpractical for clinical appli-
cations. We have shown that perivascular transplantation of micro-
incapsulated glucagon like peptide-1 (GLP1)-expressing stemcells enables
long-lasting cell retention in the ischaemic site as well as prolonged para-
crine activity, resulting in robust limb arteriogenesis (Katare et al., 2013).
Results of cytometric bead arrays on tissue collected 1 week after implan-
tation showed the expression of human angiogenic proteins in ischaemic
muscles, indicating the persistence of paracrinally active human cells.
Growing evidence suggests stem cells used in regenerativemedicine
secrete some form of extracellular vesicles, including microvesicles and
exosomes. Exosomes represent a relatively homogeneous subset of se-
cretedmembrane vesicles that are formedby direct budding of the plas-
ma membrane into early endosomes (Sahoo & Losordo, 2014).
Exosomes derived from stem cells activate angiogenesis and
cytoprotection and modulate inﬂammation and apoptosis (Lee et al.,
2012;Mackie et al., 2012; Sahoo et al., 2011). Seminal preclinical studies
from Sahoo et al. have shown that exosomesmay represent a signiﬁcant
component of the paracrine effect of stem cell transplantation for ther-
apeutic angiogenesis (Sahoo et al., 2011). Important insights are alsoSystem
Analysis
ctedwith pools ofmultiple siRNAs against singlemRNA targets from a list of pro-migratory
is collected and transferred to amulti-well plate assay for assessment of cardiac stem cell
content Cell Analyzer. (4) Data could be integratedwith results from other platforms, such
Table 1
Cardiovascular preclinical trials using stem cell-derived secretome.
Disease/delivery
Animal
model Source of CM Outcome Reference
Limb ischaemia— Daily injection of 40 μl of human
adipose-derived stem cell (ADSC) CM for 7 days





Enhanced endothelial cell growth, CD34+ cell
mobilization from bone marrow, and bone
marrow cell homing to the ischemic region,
resulting in improved blood vessel density,
limb salvage, and blood perfusion.
Bhang et al.
(2014)
Limb ischaemia— Single injection of human embryonic
stem cell-derived endothelial-like cell (ESC-EC) CM
and/or circulating proangiogenic cells (PACs) into
the gracilis muscle
SCID mice Human embryonic stem
cell-derived endothelial-like
cells
Neither diabetic PACs nor CM from ESC-ECs
improve blood ﬂow recovery and
angiogenesis. In contrast, both
transplantations of proangiogenic cells from
controls or diabetic patients supplemented




Limb ischaemia— Three weekly intramuscular
injections of endothelial progenitor cells (EPCs),





Both EPC-CM and EPCs increase limb blood
ﬂow assessed and neovascularization.
EPC-CM transplantation stimulates the




Limb ischaemia— Two intramuscular weekly injections
of human amniotic liquid derived stem cells
(AFSC) CM (topically applied to thigh muscles)
for a total treatment-duration of two weeks
SCID mice Human amniotic liquid derived
cKit stem cells
Increased arteriogenesis, capillary density,
total perfusion area, and mobility.
Mirabella
et al. (2012)
Myocardial infarction— Peri-infarct injection of
human adipose-derived stem cells (ADSC),





Improved cardiac function, reduced infarct
size, increased reparative angiogenesis,
reduced cardiomyocyte apoptosis The effect
of ADSCs on the ﬁrst 3 outcomes was superior
to that of ADSC-CM.
Yang et al.
(2013)
Myocardial infarction— Intramyocardial injections
of either concentrated CM derived from STRO-3-
mesenchymal precursor cells cultured in serum-free





Improved ventricular function, reduced




Myocardial infarction— Intravenous treatment with
CM from human embryonic stem cells-derived MSCs
or control medium initiated 4 h after coronary artery
ligation with the treatment continued for 7 days
twice daily via a catheter inserted into the jugular vein
Pigs Human embryonic stem
cells-derived MSCs
Increased capillary density, reduced infarct
size improved myocardial performance.
Timmers
et al. (2011)
Myocardial infarction— At the end of 2 h reperfusion,
three cycles of intracoronary infusion CM from porcine
endothelial progenitor cells or vehicle
Pigs Porcine peripheral blood
endothelial progenitor cells
Increased angiogenesis, improved
cardiomyocyte remodeling and contractility.
Hynes et al.
(2013)
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stem cells enhance the myocardial viability and prevent adverse heart
remodeling through a reduction in oxidative stress and Akt activation
(Arslan et al., 2013). Furthermore, exciting new research suggests that
exosomes directly communicate with the target cells by delivering spe-
ciﬁc microRNAs and other small RNAs characteristic of their parental
cell of origin (Mackie et al., 2012; Yuan et al., 2009). Analysis of
microRNAs expression in embryonic stem cell-derived exosomes re-
vealed high expression of embryonic-speciﬁc microRNAs belonging to
the miR-294 family. This microRNA regulates fundamental properties
of embryonic stem cells (ESCs), including pluripotency, cell cycle, and
proliferation and participates in the beneﬁcial effect of ESC-derived
exosomes transplantation in the injured heart (Khan et al., 2015). A re-
cent study showed the pathogenic communication between vascular
ECs and pericytes in the diabetic microvasculature is mediated by the
shedding of endothelial microparticles carrying miR-503, which trans-
fer miR-503 from ECs to vascular pericytes (Caporali et al., 2015).
To date, no clinical trial employing stem cell-derived CM for the
treatment of cardiovascular disease has been reported. Twopilot studies
described potential therapeutic activity of MSC CM for hair follicle re-
generation and resurfacing wound healing in humans (Fukuoka &
Suga, 2015; Shin, Ryu, Kwon, Park, & Jo, 2015; Zhou et al., 2013).
These initial trials are expected to encourage clinical studies for the
treatment of cardiovascular patients.
2.3. Commercialization of the stem cell secretome
The stem cell secretome is receiving increasing attention not only
from researchers but also from industry. Recently, US-based stem celltherapeutic company Stemedica announced worldwide manufacturing
license of VitriLife to their subsidiary StemProtein (Source: Stemedica
Cell Technologies, Inc.). The patent covers a novel vaporization technol-
ogy that immobilizes biologicals in glassy carbohydrates (a VitriLife™
state) thus allowing storage at room temperature for several years.
The company claims VitriLife-preserved proteins are superior in activity
compared to lyophilized proteins. The thermostable mixture from
VitriLife processed stem cell-derived CM contains therapeutic biologi-
cals, such as cytokines, chemokines, growth factors, proteins, mRNAs,
and microRNAs. The new technology may provide an efﬁcient way for
converting stem cell-derived factors into powders that retain natural ef-
ﬁcacy for eventual bulk processing and packaging of product and deliv-
ery to medical markets. Stemedica has plans to commercialize the
product formany disease conditions, from skin problems to Alzheimer's
disease, but has not released yet any information about regulatory
status.
Stemcell-derived CM in cosmetic products has been commercialized
and sold world-wide. Examples include Regenica cream made with
Human Fibroblast Serum Free CM by SkinMedica, anti-aging non-
embryonic stem cell extracts manufactured by Lifeline Skin Care, stabi-
lized CM from placenta- and umbilical cord-derived human stem cells
from Blue Horizon, and serum-free adipose-derived MSC CM from
Celprogen.
The regulatory process of CM-derived products remains vague. De-
spite the fact stem cell-derived cosmetic products have been commer-
cialized for a decade as components of skin creams, only recently Food
and Drug Administration (FDA) has pronounced a statement that
these compounds should be considered drugs under the Federal Food,
Drug, and Cosmetic Act (http://www.ipscell.com/2016/08/3-more-
Table 2
Cardiac stem cells subtypes based on antigenic characteristics.
Subtype cKit CD34 Sca-1 Abcg2 Wt1 CD105 GATA4 MEF2C NKX2–5 CD166 CD45 PDGFRα CD90 FLK1
c-Kit CSCs + − + + − + + + ± + − + ± ±
Sca-1 CSCs low − + ± + + low − + −
Side population + + + + ± − − + +
Cardiosphere-derived cells low + + + + +
Cardiac resident colony-forming unit-ﬁbroblast low + + + − + + −
Isl-1pos cardiac progenitor cells − − + +
Epicardial stem cells − + +
C-kit+ CSCs (Beltrami et al., 2003; Ellison et al., 2013) Sca1pos CSCs (Oh et al., 2003); side population (SP) cells) (Martin et al., 2004); Cardiosphere-derived cells (Chimenti et al., 2012);
cardiac resident colony-forming unit-ﬁbroblast (cCFU-Fs) (Chong et al., 2011); and the Isl-1pos cardiac progenitor cells (Laugwitz, Moretti, Caron, Nakano, & Chien, 2008); Epicardial stem
cells (Smart et al., 2011).
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keting of these productswith claims evidencing the use in the diagnosis,
cure, mitigation, treatment, or prevention of disease violates the Act. If
this applies to skin creams, even more stringent regulation should be
installed for the therapeutic use of CM in human cardiovascular
diseases.3. Exploiting the secretome of CSCs and pericytes for cardiovascular
repair
One important caveat of secretome-based therapy is represented by
the speciﬁcity of the source cell about the target tissue. It is, in fact, more
likely that a therapeutic effect is achieved by exploiting the paracrine ac-
tivity of tissue-speciﬁc cells rather than using cells isolated froma differ-
ent tissue. In this respect, CSCs and pericytes may be uniquely suited to
produce paracrine factors instrumental to cardiac and vascular repair
and regeneration.
The ﬁrst report of CSCs able to repopulate the adult heart was in
2003 (Beltrami et al., 2003). Following this initial report, several cardiac
stem/progenitor cell types have been identiﬁed based on the speciﬁca-
tion of membrane markers and transcription factors and resident CSCs
exhibit spontaneous regenerative capacity when tested in an appropri-
ate injury model (Ellison et al., 2013). Table 2 provides a summary of
different CSC subtypes based on antigenic characteristics.
Pericytes are mural cells that encircle capillaries in different organs.
Pericyte-like cells that express stem cell markers and possess
clonogenic expansion capacity have been identiﬁed in the adventitia
of large vessels fromhuman fetuses (Invernici et al., 2007) and adult in-
dividuals (Campagnolo et al., 2010). They share severalmarkers that are
typical ofmicrovascular pericytes but do not express the surfacemarker
CD146 (Table 3). Preclinical studies have shown that transplantation of
microvascular pericytes and adventitial pericyte-like stem cells exert
therapeutic actions in models of myocardial (Avolio, Meloni, et al.,
2015; Chen et al., 2013; Katare et al., 2011) and peripheral ischaemia
(Campagnolo et al., 2010; Dar et al., 2012; Gubernator et al., 2015). In
the infarctedmouse heart, combined transplantation of human adventi-
tial pericyte-like stem cells and CSCs, reduced the infarct size and im-
proved indexes of contractility by the promotion of angiogenesis,
inhibition of cardiomyocyte apoptosis, and attraction of resident and
circulating reparative cells (Avolio, Meloni, et al., 2015).Table 3
Pericyte subtypes based on antigenic characteristics.
Subtype CD146 NG2 PDGFRβ PDGFRα CD34
Microvascular pericytes + + + −
CD146-pos cardiac pericytes + + + + −
CD146-neg cardiac pericytes − + + +*
Adventitial pericyte-like stem cells − + + +*
Microvascular pericytes (Corselli et al., 2013; Dellavalle et al., 2011); CD146-pos cardiac pericy
2015); Adventitial pericyte-like stem cells (Campagnolo et al., 2010; Chen, Corselli, Peault, & H
pericyte-like stem cells but the antigen is not expressed after culture expansion of the isolatedTheultimate goal for heart repair and regeneration is to restoremus-
cle mass, and new cardiomyocyte formation following cell transplanta-
tion or ‘paracrine’ cardiac regenerative growth factor overexpression or
administration has been demonstrated in different animal models of MI
(Ellison et al., 2011; Hatzistergos et al., 2010; Koudstaal et al., 2014;
Limana et al., 2007; Loffredo et al., 2011; Madonna & De Caterina,
2011; Martin-Rendon, 2016; Nadal-Ginard, 1978, 2003; Tang et al.,
2016a,b; Wei et al., 2015). Whether these newly formed
cardiomyocytes derive from re-entry of the cell cycle of pre-existing
cardiomyocytes, or more likely from the resident eCSC population
(Loffredo et al., 2011), has yet to be determined. Moreover, there are a
number of technical limitations to prove myogenesis in these models,
and the reader is directed to comprehensive reviews on this subject
(Zebrowski et al., 2016).
3.1. Evidence for paracrine healing properties of pericytes
In 2007, Invernici et al. (2007) reported the identiﬁcation of a popu-
lation of pericyte-like cells in the human fetal aorta composed of undif-
ferentiated mesenchymal cells that coexpress endothelial and
myogenic markers. Following supplementation of the culture medium
with VEGF-A or Platelet-derived Growth Factor beta (PDGFβ), these
cells gave rise to a mixed population of mature endothelial and mural
cells. In consideration of the vascular lineage commitment, Invernici
named fetal aorta-derived cells with the term vascular progenitor cells
(VPCs). Undifferentiated VPCs produce large amounts of immunoreac-
tive VEGF-A and Angiopoietin-2 (Ang-2). Interestingly, the paracrine
pattern was profoundly altered on serum-induced VPC differentiation.
In fact, in the differentiated cell CM, the VEGF-A amount was negligible,
whereas Ang-2 and SDF-1 reached 3.5- and 7.0-fold higher levels than
in the CM of undifferentiated cells. These results indicate that VPCs pro-
duce angiogenic factors and that the concentration of these factors in
the CM varies according to cell maturation. The angiogenic properties
of human VPC CM were conﬁrmed in an in vitro proliferation assay
with human endothelial cells (ECs). The CM from VPCs stimulated the
growth of both human umbilical vascular ECs (HUVECs) and fetal
aorta ECs (FAECs), whereas CM produced by VPCs on differentiation
was ineffective. The complex angiogenic composition of VPC-derived
CM was conﬁrmed because its proangiogenic effect was reduced, but
not abolished, by the addition of anti-VEGF-A antibodies. In a subse-
quent study investigating the therapeutic activity of human VPCs inCD45 CD73 CD44 CD105 CD45 cKit CD90 CD26 CD31
− −
− + + + − − −
− + + − low −
− + + + − + + −
tes (Chen et al., 2015); CD146-neg cardiac pericytes (Avolio, Rodriguez-Arabaolaza, et al.,
uard, 2012; Klein et al., 2011). *CD34 is used for immunomagnetic sorting of adventitial
cells.
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array to identify additional proangiogenic factors. They found that un-
differentiated VPCs secrete high levels of IL-6 and IL-8, VEGF-A,
granulocyte-colony stimulating factor (G-CSF) and MCP-1. Administra-
tion of the CM from undifferentiated VPCs instead of cells supported
wound closure and neovascularization in mice, whereas the CM of dif-
ferentiated VPCs was ineffective. Furthermore, neutralizing antibodies
against VEGF-A or IL-8 inhibited the healing effect of VPC-derived CM,
thus conﬁrming the key role of both factors in wound closure and
capillarization, whereas capturing IL-6 was ineffective. Importantly,
the study delineated the signaling pathway activated by the VPC
secretome in target cells. In fact, VPC-derived CM induced the phos-
phorylation of Akt at Ser473 as well as of endothelial nitric oxide syn-
thase (eNOS) and Forkhead box protein O1 (FOXO1) in HUVECs. Also,
transfection of HUVECs with dominant-negative Akt remarkably re-
duced the pro-survival effect of CM. In consideration of the link between
the VEGF-A and Wnt pathways, Barcelos further explored the involve-
ment of Wnt in the promotion of angiogenesis by VPCs. They found
that the Wnt antagonist Secreted frizzled-related protein 1 (sFRP1),
but not Dkk-1 an inhibitor of the canonical Wnt signaling pathway,
abolishes the facilitation of wound closure and reparative angiogenesis
by VPC-derived CM. The editorial comment to Barcelos' study (Chen
et al., 2014) highlights this was the ﬁrst to demonstrate the efﬁcacy
and associated healingmechanisms of topical therapywith human pro-
genitor cell-derived CM in a preclinical model of diabetic ischemic foot
ulcer. Adding a level of complexity to this system, miR-15a and miR-
16-1 can antagonize Wnt signaling (Bonci et al., 2008). Importantly,
the two microRNAs impair the biological functions of proangiogenic
cells, and their expression is increased in the proangiogenic cells and
serum of patients with critical limb ischaemia (Spinetti et al., 2013).
Pericyte-like cells isolated and expanded from the adult saphenous
vein produce large amounts of angiogenic factors, in particular, VEGF-
A, VEGF-B, Ang-1, and miR-132, which are delivered to neighboring
ECs through the establishment of integrin-mediated interactions
(Campagnolo et al., 2010; Katare et al., 2011). Secretion of VEGF-A,
Ang-1 and miR-132 is further augmented by hypoxia/starvation,
which mimics in vitro the environment encountered by cells upon
transplantation into ischaemic tissues (Katare et al., 2011). Importantly,
anti-miR-132-transfected pericytes were inferior to naïve pericytes orRegeneration
Remo
Tissue engineering
Fig. 2. Paracrine action of pericytes. Isolated from small surgical leftovers of vascular or cardiac
release paracrine factors that (1) improve cardiomyocyte survival and inhibit ﬁbrosis, there
recruitment of endogenous stem cells. In the case of tissue engineering, repopulation of valvu
production and release of collagen.scrambled-transfected pericytes in improving reparative angiogenesis
in the infarcted mouse heart. Nonetheless, the improvement afforded
by pericytes was not completely abrogated by the miR-132 silencing,
thus suggesting the participation of miR-132-dependent and indepen-
dent mechanisms (Katare et al., 2011). Fig. 2 summarizes the spectrum
of the in vivo paracrine interactions between transplanted pericytes and
resident cardiomyocytes, CSCs, and ECs.
It has been acknowledged that direct contact and paracrine signaling
between different stem cell populations can induce functional changes
and inﬂuence the susceptibility to a variety of stressors. Also, competi-
tive interaction between stem cells within their native niches reported-
ly results in survival of the ﬁttest stem cells and death of the most
susceptible cells (Leri & Anversa, 2013). We further elaborated this in-
triguing concept by assessing the reciprocal cross-talk between saphe-
nous vein-derived pericytes and c-Kit CSCs (Avolio, Meloni, et al.,
2015). Intra-myocardial injection of adventitial pericytes or CSCs, as a
single or combined therapy, increases the abundance of primitive c-
Kit + cells in the peri-infarct zone. Also, the CM of the 2 populations ex-
erts a potent chemoattractant activity on murine CSCs, without
inﬂuencing their proliferation or viability. The two cell populations re-
lease similar levels of Hepatocyte Growth Factor (HGF) and stem cell
factor (SCF), with no substantial changes in normoxia versus hypoxia
or monoculture versus coculture. On the other hand, pericytes secrete
the proangiogenic factors Ang-1 and Ang-2 at higher concentrations
than CSCs, and a similar trend was observed with bFGF. Interestingly,
the secretion of angiopoietins and bFGF by cells in coculture was
lower than the average of the 2 cell preparations, thus indicating a neg-
ative reciprocal interference. Moreover, hypoxia induced an increase in
the secretion of VEGF-A by CSCs, but this effectwas not appreeeciated in
the coculture. ConcerningmiR-132 secretion, hypoxia increased its level
in pericyte CM, while reducing it CSC CM. An additive effect of the cell
coculture was instead noted in the secretion of SDF-1α both under
normoxia and hypoxia. Altogether, these data indicate a multifaceted
interactive behavior at the level of secretome, which may result in at-
tenuated secretion of VEGF-A, Ang-1, Ang-2, bFGF, andmiR-132 in com-
parison with the prominent cell producer, but the synergic release of
SDF-1. To determine whether these phenomena are transcriptionally
modulated, we performed quantitative polymerase chain reaction anal-
yses of angiopoietins and SDF-1 mRNA levels in pericytes and CSCs,Angiogenesis
delling
tissue, pericytes are transplanted in the heart or used for valvular tissue engineering. They
fore preventing adverse remodeling; (2) exert proangiogenic activity; and (3) promote
lar grafts with pericytes may help the renewal of extracellular matrix protein s through
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duces the expression of Ang-2 in both the cell types. Also, CSCs exposed
to pericyte CM showed reduced SDF-1 mRNA levels as compared with
CSCs exposed to the unconditioned medium. These data suggest a tran-
scriptional interference on Ang-2 and SDF-1. However, while Ang-2 ex-
pression was reduced at mRNA and protein level, the increase in SDF-1
content in coculture media was not attributed to the induction of gene
transcription, but rather to an increase in secretion rate. Exploring a pos-
sible involvement of Dipeptidyl peptidase-4 (DPP-4) we found higher
expression levels by CSCs. Furthermore, DPP-4 is downregulated at
mRNAand protein level in CSCs exposed to pericytes CM. These ﬁndings
may have important implication for association cell therapy, where the
outcomemay depend on the balance between cooperative and compet-
itive interactions at the level of the secretome. For instance, in our study,
the combined transplantation of pericytes and CSCs additively reduced
the infarct size and promoted vascular proliferation and arteriogenesis,
but did not surpass single therapies concerning contractility indexes
(Avolio, Meloni, et al., 2015).
Skeletal muscle-derived stem cells have been among the ﬁrst cell
therapy models for regenerative treatment of the infarcted heart
(Menasche, 2008). A recent study investigated the therapeutic potential
of human skeletal muscle pericytes for treating ischaemic heart disease
and mediating associated repair mechanisms in mice (Chen et al.,
2013). The authors found that pericyte transplantation attenuates left
ventricular dilatation andmyocardialﬁbrosis and improves cardiac con-
tractility in infarcted mouse hearts. In line with ﬁndings in saphenous
vein-derived pericytes, hypoxia-induced the expression of VEGF-A as
well as PDGF-β, TransformingGrowth Factor beta1 (TGF-β1), and corre-
sponding receptors while expression of bFGF, HGF, and Ang-1 was
repressed.3.2. Resident cardiac pericytes: are they better suited for the heart?
New knowledge on microvessel-associated regenerative precursor
cells in cardiacmuscle opens prospectives for organ-speciﬁc treatments
of patients with congenital and acquired heart defects. Peault's team
showed that microvascular pericytes within the human myocardium
exhibit phenotypes and multipotency similar to their anatomically
and developmentally distinct counterparts (Chen et al., 2015). Howev-
er, they have no ability for skeletalmyogenesis, diverging in this respect
from pericytes of all other origins. In contrast, a cardiomyogenic poten-
tial was evidenced both in vitro and after intra-myocardial transplanta-
tion in vivo.
Using the same standard operating protocol employed for the deri-
vation of pericytes from adult saphenous veins, we have isolated and
expanded pericyte-like progenitors from small biopsies of congenitally
defective hearts (antigenic features illustrated in Table 3) (Avolio,
Rodriguez-Arabaolaza, et al., 2015). The long-term objective of research
on neonatal cardiac pericytes is their perusal for deﬁnitive correction of
congenital heart defects (Avolio, Caputo, &Madeddu, 2015). A spectrum
of prostheses in the form of conduits, patches, and valves is employed in
congenital cardiac surgery, but none of them is perfect. In particular,
currently, available grafts do not possess growing capacity and become
incompetent with time, thus requiring surgical replacement. The basic
concept of tissue engineering is to create living material made by
cellularized grafts that, once implanted into the heart, grows and re-
models in parallel with the recipient organ. Neonatal pericytes produce
a powerful secretome uniquely ﬁt for the purpose. This includes growth
factors that promote vasculogenesis and cardiomyogenesis and
chemokines able to attract ECs and endothelial progenitor cells
instrumental to graft endothelialisation. Comparison with saphenous
vein–derived pericytes indicates similarity of the 2 cell populations,
though cardiac pericytes secrete more HGF (6-fold), Ang-2 (8-fold),
bFGF (4-fold), and VEGF-A (6-fold) than saphenous vein–derived
pericytes. Furthermore, neonatal cardiac pericytes release procollagentype 1, a major constituent of the cardiac extracellular matrix, which
is fundamental to the maintenance of graft integrity.
The umbilical cord represents a valuable source of stem cells imme-
diately available at birth for corrective strategies. In a recent study,
human cord-derived pericytes or cord blood-derived MSCs were deliv-
ered before or after alveolar injury into the airways of newborn rats ex-
posed to hyperoxia, a model of bronchopulmonary dysplasia which
complicates extreme prematurity and currently lacks efﬁcient treat-
ment (Pierro et al., 2013). Rat pups exposed to hyperoxia showed typi-
cal alteration in alveolar growth with enlargement and loss of lung
capillaries. Both human cord-derived pericytes and cord blood-derived
MSCs partially prevented and rescued lung function and structure.
However, the low cell engraftment suggested a paracrine effect. In
line, cell free-derived CM from both cell types manifested signiﬁcant
beneﬁt when used either prophylactically or therapeutically. Altogeth-
er, these studies open new avenues to exploit pericytes in neonatal
regenerative medicine.
4. Evidence for paracrine healing properties of cardiac stem/progen-
itor cells
There is a growing consensus that the beneﬁcial effects of any myo-
cardial autologous or allogeneic cell therapy so far tested is, at least in
part, mediated by a paracrine effect on the patient's cells at risk and ac-
tivation of the host's CSCs by growth factors secreted by the
transplanted cells (Braunwald, 2015; Lorkeers et al., 2014). Major con-
tributors to this cardioprotective and CSC stimulatory effect are HGF
and IGF-1 acting through their relative receptors present both on the
myocytes, vascular and CSCs of the recipient's heart (Ellison et al.,
2011).
MSCs have a broad repertoire of secreted trophic and immunomod-
ulatory cytokines; however, they also secrete factors that negatively
modulate cardiomyocyte apoptosis, inﬂammation, scar formation, and
pathological remodeling (Ranganath et al., 2012). Moreover, it is ques-
tionablewhether they are themost optimal cell to use regarding surviv-
al and homing to and engraftment in the myocardium. Furthermore,
cells can become entrapped in the microvasculature and impede cell
entry into the myocardium.
The safety and efﬁcacy of transplanting 2 million allogeneic, mis-
matched Cardiosphere-derived cells (CDCs) was tested in infarcted
rats. Three weeks post-MI, animals that received allogeneic CDCs exhib-
ited smaller scar size, increased infarcted wall thickness, and attenua-
tion of ventricular remodeling. Allogeneic CDC transplantation
resulted in an improved fractional area change (∼12%), ejection fraction
(∼20%), and fractional shortening (∼10%), and this was sustained for at
least 6 months. Furthermore, allogeneic CDCs stimulated endogenous
regenerative mechanisms (cardiomyocyte cycling, recruitment of en-
dogenous CSCs, angiogenesis) and increased levels of myocardial
VEGF, IGF-1, and HGF (Malliaras et al., 2014).
We have previously shown that CSCs that express high levels of the
transcription factor GATA-4 exert a paracrine survival effect on
cardiomyocytes through increased IGF-1.
secretion and induction of the IGF-1R signaling pathway
(Kawaguchi et al., 2010). Furthermore, unlike bone marrow derived
cells (Hofmann et al., 2005), CSCs have a very high tropism for themyo-
cardium (Ellison et al., 2013). This cardiac tropism is governed by the
SDF1-CXCR4 signaling axis, and when CSCs are injected either
intracoronary or systemically, they home to and nest into the damaged
heart with a high efﬁciency and signiﬁcantly restore the myocardium,
anatomically and functionally (Ellison et al., 2013).
Cloned male eGFP-transduced heterologous HLA not-matched por-
cine CSCs, were administered intracoronary at differential doses
(5 × 106, 5 × 107 and 1 × 108) in 3 groups of pigs, 30min after coronary
reperfusion. Pig serumwas injected to 6 control pigs after MI. BrdUwas
administered via osmotic pumps to track myocardial regeneration. Pigs
were sacriﬁced at 30 min, 1 and 21 days. We found that heterologous
Fig. 3. Through paracrine mechanisms, c-kitpos heterologous HLA non-matched CSC treatment preserves myocardial wall structure and attenuates remodeling in a porcine MI model.
(A) CSC treatment led to signiﬁcantly decreased myocyte hypertrophy in the border region. *P b 0.05 vs. CTRL. (B) Representative H&E staining showing a band of hypertrophic
myocytes in the border region of CTRL pig myocardium. (C) CSC treatment signiﬁcantly decreased percent number of apoptotic (caspase 3 positive) myocytes in the border region.
*P b 0.05 vs. CTRL. (D & E) Representative images of sirius red staining to identify ﬁbrotic tissue (red) and muscle (yellow) in the infarct region of CTRL (D) and CSC-treated (E) pig
hearts. (F) CSC-treated pig hearts had a decreased percentage area fraction of ﬁbrosis in the infarct zone.*P b 0.05 vs. CTRL.
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nested into the damaged myocardium with an efﬁciency of N95%, at
30min through to 1 day after MI. Minimal spill over of CSCswas detect-
ed in the coronary sinus, spleen, lung or live and all injected CSCs had
disappeared from the myocardium at 21 days. CSC-treated infarcted
pig hearts showed a signiﬁcant increase in the number of endogenous
c-kitpos (GFPneg) CSCs in the border and infarct regions, compared to
CTRL. CSC-treated hearts exhibited an increase in the number of small,
newly formed BrdUpos myocytes and capillaries. CSC injection signiﬁ-
cantly preserved myocardial wall structure and attenuated remodeling
by reducing hypertrophy, apoptosis and ﬁbrosis (Fig. 3). Moreover, car-
diac function was signiﬁcantly preserved/improved by heterologous
CSC-treatment. To summarize, intracoronary injection of heterologous
CSCs after MI in pigs, which is a clinically relevant MI model, activates
the endogenous CSCs through a paracrine mechanism resulting in im-
proved myocardial cell survival and physiologically meaningful regen-
eration (Ellison et al., 2009).
Allogeneic CSC therapy is conceptually and practically different from
any presently in clinical use. The proposed cell therapy is only a different
form of growth factor therapy, where the cells naturally home to the
damaged myocardium, deliver a more complex mixture of growth fac-
tors, elicit a ‘paracrine’ effect and activate the endogenous target cells.
Then the allogeneic CSCs are eliminated, and the regeneration triggered
by activated endogenous CSCs is completely autologous. Therefore, the
allogeneic CSCs survived long enough in the allogeneic host to produce
their paracrine effect before being eliminated by the host immune sys-
tem. Once more information is available, the allogeneic cells could be
used either alone or in combination with the available factor therapy
to improve the activation of the CSCs and the maturation of their
progeny.
5. Conclusions
The market analysis predicts protein and peptide-based drugs will
compose N50%of novel drugswithin the next 10 years. Pharmacological
companies have been using unbiased discovery methods to generate
new druggable compounds since many years. The approach is nowincreasingly used in academic research. It is likely that new cardiovascu-
lar drugs will be introduced in the next future by applying these ap-
proaches to the study of stem cell paracrine function. Due to the
variability of the product and high costs associated with clinical grade
production, stem cell-based therapy is not amenable to the majority of
ischaemic patients. The use of drugs inspired by the stem cell secretome
will instead offer unprecedented therapeutic opportunities, resulting in
a fundamental shift in the initial concept of regenerative medicine.
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